Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients

Launched by XIE CONGYING · Dec 19, 2012

Keywords

ClinConnect Summary

Cervical carcinoma is one of the most common gynecologic cancers worldwide. Early stage cervical cancer can be treated effectively with either radiotherapy or radical hysterectomy plus pelvic lymph node dissection. However, several pathological risk factors, such as lymph node metastasis, the involvement of vaginal resection margin, and the parametrial invasion, have been identified to compromise the patient prognosis.

Concurrent radiotherapy with cisplatin-based chemotherapy has become the standard treatment for patients with cervical cancer. However, many patients with pathological risk ...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Undertaken radical hysterectomy with diagnosis of invasive cervical cancer I a2-II b (non-small cell type)
• • One or more risk factors (lymph node involvement, resection margin involvement, parametrial involvement)
• • Eastern Cooperative Oncology Group 0-2
• • Expected life span over 6 months.
• • No distant metastasis
• • Adequate bone marrow functions (absolute neutrophil count≥ 1,500/ul, blood platelet≥ 100,000/ul, haemoglobin≥ 10g/dl)
• • Adequate renal functions(serum creatinine ≤ 1.5mg/dl)
• • Adequate liver functions (serum bilirubin ≤ 1.5mg/dl, aspartate aminotransferase/alanine aminotransferase ≤ 3 times(normal value)
• • Written informed consent
• Exclusion Criteria:
• • Previous history of chemotherapy or radiation
• • Hypersensitive reaction to platinum/paclitaxel agent
• • History of other cancer
• • Concurrent systemic illness not appropriate for chemotherapy
• • Active infection requiring antibiotics
• • Pregnancy
• • Metastasis to paraaortic lymph node